S 977
116th Congress
Senate
Health
Asia
Canada
Consumer affairs
Employee benefits and pensions
Europe
France
Germany
Health care costs and insurance
Health care coverage and access
Inflation and prices
Japan
Prescription drugs
Retail and wholesale trades
United Kingdom
Transparent Drug Pricing Act of 2019
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 1, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 1, 2019
Introduced in Senate
Plain-English summary
Transparent Drug Pricing Act of 2019
This bill establishes several requirements relating to the prices of prescription drugs.
For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period.
The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.
What's happening now
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
1
Cosponsors
1